Search
20-ketosteroid reductase (20-hydroxysteroid dehydrogenase)
go.drugbank.com/bio_entities/BE0009795EnzymeHumans and other mammalsCytosolic aldo-keto reductase that catalyzes NADPH-dependent reduction of ketosteroids to hydroxysteroids. Displays broad substrate specificity with distinct positional and stereochemistry, primarily generating 20alpha-hydroxysteroids, b...
Synonyms: CHDRGenistein
go.drugbank.com/drugs/DB01645InvestigationalIt has shown to be effective in the treatment of common liver fluke, pork trematode and poultry cestode. … It has been determined to be the active ingredient in <I>Felmingia vestita</I>, which is a plant traditionally used against worms.
Cinalukast
go.drugbank.com/drugs/DB00587ExperimentalUsed in the treatment of asthma, cinalukast selectively antagonizes leukotriene D4 (LTD4) at the cysteinyl leukotriene receptor, CysLT1, in the human airway. … Cinalukast inhibits the actions of LTD4 at the CysLT1 receptor, preventing airway edema, smooth muscle contraction, and enhanced secretion of thick, viscous mucus.
Synonyms: 3'-((E)-2-(4-cyclobutyl-2-thiazolyl)vinyl)-2,2-diethylsuccinanilic acidPimagedine
go.drugbank.com/drugs/DB05383InvestigationalIt is beneficial in treating patients with diabetic nephropathy. … It is an advanced glycation end product inhibitor which manages diabetic nephropathy, either alone or in combination with other therapies.
Allovectin-7
go.drugbank.com/drugs/DB17439InvestigationalIt was discontinued after it failed to improve the objective response rate or overall survival versus first-line chemotherapy in malignant melanoma.[A255207]
Vapreotide
go.drugbank.com/drugs/DB04894InvestigationalIt was being studied for the treatment of cancer.
Mavorixafor
go.drugbank.com/drugs/DB05501ApprovedInvestigational[L50642] It was first approved by the FDA on April 30, 2024, for the treatment of warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome, a genetic immunodeficiency disorder characterized
Cytisine
go.drugbank.com/drugs/DB09028InvestigationalRecent studies have shown it to be a more effective and significantly more affordable smoking cessation treatment than nicotine replacement therapy. … Recent Phase III clinical trials using Tabex (a brand of Cytisine marketed by Sopharma AD) have shown similar efficacy to varenicline, but at a fraction of the cost.